DP
PMVP icon

Diadema Partners’s PMV Pharmaceuticals PMVP Stock Holding History

Diadema Partners’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,300
Closed -$15.8K – 180
2025
Q3 		$15.8K Buy
+11,300
New +$15.6K ﹤0.01% 126

Other funds holding PMVP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Diadema Partners's PMVP Position: Q4 2025 in Review

Diadema Partners sold out of PMV Pharmaceuticals (PMVP) in Q4 2025, closing a stake of 11,300 shares — an estimated $15.8K sold.

Diadema Partners first reported a position in PMVP in Q3 2025 and held it in 1 quarter. The position peaked at $15.8K in Q3 2025. 63 funds tracked by Wall St. Rank hold PMVP as of Q4 2025.

  • Diadema Partners reported no remaining PMV Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Diadema Partners sold 11,300 PMV Pharmaceuticals shares in Q4 2025, an estimated $15.8K.
  • Diadema Partners first reported a position in PMV Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Diadema Partners's PMV Pharmaceuticals position peaked at $15.8K in Q3 2025.
  • 63 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q4 2025.

Based on Diadema Partners's 13F filing for Q4 2025, filed 17 Feb 2026.